The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Open accessAbstract
IMPORTANCE: Several studies have reported antidepressant effects of anti-inflammatory treatment; however, the results have been conflicting and detrimental adverse effects may contraindicate the use of anti-inflammatory agents. OBJECTIVE: To systematically review the antidepressant and possible adverse effects of anti-inflammatory interventions. DATA SOURCES: Trials published prior to December, 31, 2013, were identified searching Cochrane Central Register of Controlled Trials, PubMed, EMBASE, PsychINFO, Clinicaltrials.gov, and relevant review articles. STUDY SELECTION: Randomized placebo-controlled trials assessing the efficacy and adverse effects of pharmacologic anti-inflammatory treatment in adults with depressive symptoms, including those who fulfilled the criteria for depression. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 independent reviewers. Pooled standard mean difference (SMD) and odds ratios (ORs) were calculated. MAIN OUTCOMES AND MEASURES: Depression scores after treatment and adverse effects. RESULTS: Ten publications reporting on 14 trials (6262 participants) were included: 10 trials evaluated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (n=4,258) and 4 investigated cytokine inhibitors (n=2,004). The pooled effect estimate suggested that anti-inflammatory treatment reduced depressive symptoms (SMD, -0.34; 95% CI, -0.57 to -0.11; I2=90%) compared with placebo. This effect was observed in studies including patients with depression (SMD, -0.54; 95% CI, -1.08 to -0.01; I2=68%) and depressive symptoms (SMD, -0.27; 95% CI, -0.53 to -0.01; I2=68%). The heterogeneity of the studies was not explained by differences in inclusion of clinical depression vs depressive symptoms or use of NSAIDs vs cytokine inhibitors. Subanalyses emphasized the antidepressant properties of the selective cyclooxygenase 2 inhibitor celecoxib (SMD, -0.29; 95% CI, -0.49 to -0.08; I2=73%) on remission (OR, 7.89; 95% CI, 2.94 to 21.17; I2=0%) and response (OR, 6.59; 95% CI, 2.24 to 19.42; I2=0%). Among the 6 studies reporting on adverse effects, we found no evidence of an increased number of gastrointestinal or cardiovascular events after 6 weeks or infections after 12 weeks of anti-inflammatory treatment compared with placebo. All trials were associated with a high risk of bias owing to potentially compromised internal validity. CONCLUSIONS AND RELEVANCE: Our analysis suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms without increased risks of adverse effects. However, a high risk of bias and high heterogeneity made the mean estimate uncertain. This study supports a proof-of-concept concerning the use of anti-inflammatory treatment in depression. Identification of subgroups that could benefit from such treatment might be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who receive cytokine treatments such as IL-2 or IFN γ as part of their treatment for hepatitis or cancer often develop depressive symptoms 82”
From Major depressive disorder (2016) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Kohler and colleagues found that patients prescribed celecoxib compared to placebo were 7 times more likely to respond to an antidepressant with no increased risks of GI or CV effects (155).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“blockade of cytokines, such as TNF, or of inflammatory signalling pathway components, such as cyclooxygenase 2, has been shown to reduce depressive symptoms in patients with medical illnesses, including rheumatoid arthritis, psoriasis and cancer, as well as in patients with major depressive disorder27–29.”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, it appears that anti-inflammatory agents may only demonstrate effective antidepressant activity in subgroups of patients who show evidence of increased peripheral inflammation, for example individuals with medical conditions including osteoarthritis and psoriasis that are characterized by increased levels of peripheral inflammation and patients with depression with increased”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“depressive symptoms are more frequent in patients with conditions involving inflammation (e.g., autoimmune diseases) and can be reversed through the use of anti-inflammatory drugs (Kojima et al., 2009; Köhler et al., 2014).”
From The interplay between stress, inflammation, and emotional attention: relevance for depression (2019) · cites this paper as Köhler et al., 2014
In the citing paper
“There is also meta-analytic evidence that anti-inflammatory treatments can be effective means for treating depression (Köhler et al., 2014).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Köhler et al., 2014
In the citing paper
“A meta-analysis of nonsteroidal anti-inflammatory drugs and cytokine inhibitors suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms in individuals with major depression or with clinically significant depressive symptoms198.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [198]
In the citing paper
“There is particular interest in how inflammatory cell types in the brain cause depressive symptoms, as anti-inflammatory treatments reduce depressive symptoms in humans [173] and chronic stress enhances inflammation in animal models [174].”
From The molecular and cellular mechanisms of depression: a focus on reward circuitry (2019) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Gluud, L. L., Villumsen, J., & Gluud, C. N. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,266
The case of the misleading funnel plot
Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H., & Olkin, I. (2006) · BMJ · doi:10.1136/bmj.333.7568.597 · Cited by 1,766
Research works printed but not linked: 2
- [24]24. Raison C, Rutherford RE, Woolwine B, et al. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation. Brain Behav Immun. 2012;26(suppl 1):S49. doi:10.1016/j.bbi.2012.07.200.W. · DOI
- [27]27. Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol Bul. 2011;21:S183-S184.
Cited by
Sorted by citations
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Kandola, A., Ashdown-Franks, G., Hendrikse, J., Sabiston, C. M., & Stubbs, B. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.040 · Cited by 1,309
Haapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.001 · Cited by 1,129
Depression and obesity: evidence of shared biological mechanisms
Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C., & Penninx, B. W. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0017-5 · Cited by 1,073
Depression as a Microglial Disease
Yirmiya, R., Rimmerman, N., & Reshef, R. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.08.001 · Cited by 944
Osimo, E. F., Pillinger, T., Rodriguez, I. M., Khandaker, G. M., Pariante, C. M., & Howes, O. D. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.02.010 · Cited by 937
Inflammation: Depression Fans the Flames and Feasts on the Heat
Kiecolt-Glaser, J. K., Derry, H. M., & Fagundes, C. P. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15020152 · Cited by 844
Peng, Y., Ao, M., BaoHua, D., Jiang, Y., Yu, L., Chen, Z., Hu, C.-J., & Xu, R. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s327378 · Cited by 916
Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019) · Psychological Medicine · doi:10.1017/s0033291719001454 · Cited by 774
Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.167 · Cited by 659
The Role of Inflammation in Depression and Fatigue
Lee, C.-H., & Giuliani, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01696 · Cited by 662
Neuroimmune mechanisms of depression
Hodes, G. E., Kana, V., Menard, C., Merad, M., & Russo, S. J. (2015) · Nature Neuroscience · doi:10.1038/nn.4113 · Cited by 585
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Pathogenesis of depression: Insights from human and rodent studies
Ménard, C., Hodes, G. E., & Russo, S. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.053 · Cited by 593
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications
Penninx, B. W. J. H., & Lange, S. M. M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/bpenninx · Cited by 566
Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression
Wang, H., He, Y., Sun, Z., Ren, S., Liu, M., Wang, G., & Yang, J. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02492-0 · Cited by 605
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“IDO enzyme inhibitors QUIN (138) Overstimulates the NMDA receptor resulting in glutamatergic excitotoxicity GSK-3β inhibitors COX-2 (155) COX-2 increases PGE-2 resulting in glutamatergic excitability, stimulation of CRF, and the release of pro-inflammatory cytokines COX-2 inhibitors Proteoglycans (152) Reactive astroc…”
BackgroundInfluentialInflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516
Self-citationMicroglial regional heterogeneity and its role in the brain
Tan, Y.-L., Yuan, Y., & Tian, L. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0609-8 · Cited by 571
Inflammation in psychiatric disorders: what comes first?
Bauer, M. E., & Teixeira, A. L. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13712 · Cited by 500
Immunoneuropsychiatry — novel perspectives on brain disorders
Pape, K., Tamouza, R., Leboyer, M., & Zipp, F. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0174-4 · Cited by 461
Inflammation Effects on Motivation and Motor Activity: Role of Dopamine
Felger, J. C., & Treadway, M. T. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.143 · Cited by 474
Köhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432
Self-citationDepression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression
Milaneschi, Y., Lamers, F., Berk, M., & Penninx, B. W. J. H. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.014 · Cited by 451
Imaging the Role of Inflammation in Mood and Anxiety-related Disorders
Felger, J. C. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666171123201142 · Cited by 447
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
Rheumatoid arthritis and depression: an inflammatory perspective
Nerurkar, L., Siebert, S., McInnes, I. B., & Cavanagh, J. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30255-4 · Cited by 426
Inflammation and post‐traumatic stress disorder
Hori, H., & Kim, Y. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12820 · Cited by 437
Psychoneuroimmunology of early-life stress: the hidden wounds of childhood trauma?
Danese, A., & J Lewis, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.198 · Cited by 393
Wang, A. K., & Miller, B. J. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx035 · Cited by 389
Immune and neuroendocrine mechanisms of stress vulnerability and resilience
Ménard, C., Pfau, M. L., Hodes, G. E., & Russo, S. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.90 · Cited by 374
Depression in cancer: The many biobehavioral pathways driving tumor progression
Bortolato, B., Hyphantis, T. N., Valpione, S., Perini, G., Maes, M. H. J., Morris, G., Kubera, M., Köhler, C. A., Fernandes, B. S., Stubbs, B., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.004 · Cited by 399
Immune targets for therapeutic development in depression: towards precision medicine
Drevets, W. C., Wittenberg, G. M., Bullmore, E. T., & Manji, H. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00368-1 · Cited by 348
Sex differences in the neuro-immune consequences of stress: Focus on depression and anxiety
Bekhbat, M., & Neigh, G. N. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.02.006 · Cited by 376
Beyond a neurotransmitter: The role of serotonin in inflammation and immunity
Wu, H., Denna, T., Storkersen, J., & Gerriets, V. A. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.015 · Cited by 357
Neurobiology of Resilience: Interface Between Mind and Body
Cathomas, F., Murrough, J. W., Nestler, E. J., Han, M.-H., & Russo, S. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.04.011 · Cited by 296
Iob, E., Kirschbaum, C., & Steptoe, A. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0501-6 · Cited by 305
Evaluation of various estimators for standardized mean difference in meta‐analysis
Lin, L., & Aloe, A. M. (2021) · Statistics in Medicine · doi:10.1002/sim.8781 · Cited by 297
Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711708 · Cited by 279
Hidden wounds? inflammatory links between childhood trauma and psychopathology
Danese, A., & Baldwin, J. R. (2017) · Annual Review of Psychology · doi:10.1146/annurev-psych-010416-044208 · Cited by 286
Köhler-Forsberg, O., Buttenschøn, H. N., Tansey, K. E., Maier, W., Hauser, J., Dernovsek, M. Z., Henigsberg, N., Souery, D., Farmer, A., Rietschel, M., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.02.020 · Cited by 283
Self-citationCalipari, E. S., Godino, A., Peck, E. G., Salery, M., Mervosh, N. L., Landry, J. A., Russo, S. J., Hurd, Y. L., Nestler, E. J., & Kiraly, D. D. (2017) · Nature Communications · doi:10.1038/s41467-017-01881-x · Cited by 281
The microbiome, immunity, and schizophrenia and bipolar disorder.
Dickerson, F., Severance, E., & Yolken, R. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.12.010 · Cited by 268
Rapaport, M. H., Nierenberg, A. A., Schettler, P. J., Kinkead, B. L., Cardoos, A., Walker, R., & Mischoulon, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.22 · Cited by 275
Kappelmann, N., Arloth, J., Georgakis, M. K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G. M., & Binder, E. B. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3436 · Cited by 270
Rosenblat, J., & McIntyre, R. (2017) · Brain Sciences · doi:10.3390/brainsci7110144 · Cited by 258
Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320912 · Cited by 235
Nettis, M. A., Lombardo, G., Hastings, C., Zajkowska, Z., Mariani, N., Nikkheslat, N., Worrell, C., Enache, D., McLaughlin, A., Kose, M., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00948-6 · Cited by 235
Microbiome, inflammation, epigenetic alterations, and mental diseases
Alam, R., Abdolmaleky, H. M., & Zhou, J. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32567 · Cited by 240
Milaneschi, Y., Lamers, F., Peyrot, W. J., Baune, B. T., Breen, G., Dehghan, A., Forstner, A. J., Grabe, H. J., Homuth, G., Kan, C., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3016 · Cited by 233
Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233
Orlovska‐Waast, S., Köhler‐Forsberg, O., Brix, S. W., Nordentoft, M., Kondziella, D., Krogh, J., & Benros, M. E. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0220-4 · Cited by 233
Self-citationPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
The molecular and cellular mechanisms of depression: a focus on reward circuitry
Fox, M. E., & Lobo, M. K. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0415-3 · Cited by 232
Pu, J., Liu, Y., Zhang, H., Tian, L., Gui, S., Yu, Y., Chen, X., Chen, Y., Yang, L., Ran, Y., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0645-4 · Cited by 252
Lamers, F., Milaneschi, Y., Smit, J. H., Schoevers, R. A., Wittenberg, G. M., & Penninx, B. W. J. H. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.020 · Cited by 225
Antidepressant therapies inhibit inflammation and microglial M1-polarization
Kalkman, H. O., & Feuerbach, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.001 · Cited by 212
Syed, S. A., Beurel, E., Loewenstein, D., Lowell, J. A., Craighead, W. E., Dunlop, B. W., Mayberg, H. S., Dhabhar, F. S., Dietrich, W. D., Keane, R. W., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.08.001 · Cited by 214
NLRP1 inflammasome contributes to chronic stress-induced depressive-like behaviors in mice
Song, A., Gao, B., Fan, J.-J., Zhu, Y., Zhou, J., Wang, Y., Xu, L.-Z., & Wu, W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01848-8 · Cited by 215
Szymkowicz, S. M., Gerlach, A., Homiack, D., & Taylor, W. D. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02464-9 · Cited by 234
Rosenblat, J. D., Kakar, R., Berk, M., Kessing, L. V., Vinberg, M., Baune, B. T., Mansur, R. B., Brietzke, E., Goldstein, B. I., & McIntyre, R. S. (2016) · Bipolar Disorders · doi:10.1111/bdi.12373 · Cited by 199
The interplay between stress, inflammation, and emotional attention: relevance for depression
Maydych, V. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00384 · Cited by 193
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
Immunopsychiatry: important facts
Khandaker, G. M., Dantzer, R., & Jones, P. B. (2017) · Psychological Medicine · doi:10.1017/s0033291717000745 · Cited by 205
Depression and diabetes: treatment and health-care delivery
Petrak, F., Baumeister, H., Skinner, T. C., Brown, A. D. H., & Holt, R. I. G. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00045-5 · Cited by 196
Metabolic and inflammatory markers: associations with individual depressive symptoms
Lamers, F., Milaneschi, Y., de Jonge, P., Giltay, E. J., & Penninx, B. W. J. H. (2017) · Psychological Medicine · doi:10.1017/s0033291717002483 · Cited by 202
Hou, R., Garner, M., Holmes, C., Osmond, C., Teeling, J., Lau, L., & Baldwin, D. S. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.01.021 · Cited by 191
Examining the role of neuroinflammation in major depression
Furtado, M., & Katzman, M. A. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.06.009 · Cited by 199
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Abdallah, C. G., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., Sherif, M., Ahn, K.-H., D’Souza, D. C., Formica, R., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0644-9 · Cited by 184
Peripheral Blood Cell–Stratified Subgroups of Inflamed Depression
Lynall, M.-E., Turner, L., Bhatti, J., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D., Drevets, W. C., Cowen, P., Harrison, N. A., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.11.017 · Cited by 187
van Dooren, F. E. P., Schram, M. T., Schalkwijk, C. G., Stehouwer, C. D. A., Henry, R. M. A., Dagnelie, P. C., Schaper, N. C., Kallen, C., Koster, A., Sep, S. J. S., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.03.004 · Cited by 191
Wittenberg, G. M., Stylianou, A., Zhang, Y., Sun, Y., Gupta, A., Jagannatha, P. S., Wang, D., Hsu, B. L., Curran, M. E., Khan, S. A., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0471-8 · Cited by 194
Kiraly, D. D., Horn, S. R. G.-V., Dam, N. T. V., Costi, S., Kirshenbaum, J. S., Kim‐Schulze, S., Patel, M., Hodes, G. E., Russo, S. J., Mérad, M., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.31 · Cited by 189
Wang, L., Wang, R., Liu, L., Qiao, D., Baldwin, D. S., & Hou, R. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.02.021 · Cited by 192
Rong, H., Xie, X., Zhao, J., Lai, W., Wang, M., Xu, D., Liu, Y., Guo, Y., Xu, S., Deng, W.-F., et al. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.03.017 · Cited by 185
Frank, P., Jokela, M. M., Batty, G. D., Cadar, D., Steptoe, A., & Mika Kivimaki, B. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.20121776 · Cited by 192
Baumeister, D., Ciufolini, S., & Mondelli, V. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4044-5 · Cited by 183
Abautret-Daly, Á., Dempsey, E., Parra‐Blanco, A., Medina, C., & Harkin, A. (2017) · Acta Neuropsychiatrica · doi:10.1017/neu.2017.3 · Cited by 186
Rosenblat, J. D., & McIntyre, R. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.042 · Cited by 179
Dooley, L. N., Kuhlman, K. R., Robles, T. F., Eisenberger, N. I., Craske, M. G., & Bower, J. E. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.09.006 · Cited by 176
The role of the immune system in posttraumatic stress disorder
Katrinli, Ş., Oliveira, N. C. D. S., Felger, J. C., Michopoulos, V., & Smith, A. K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02094-7 · Cited by 201
Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders
Furtado, M., & Katzman, M. A. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.05.036 · Cited by 174
Davis, M. T., Holmes, S. E., Pietrzak, R. H., & Esterlis, I. (2017) · Chronic Stress · doi:10.1177/2470547017710916 · Cited by 194
The microbiota, immunoregulation, and mental health: implications for public health
Lowry, C. A., Smith, D. G., Siebler, P. H., Schmidt, D., Stamper, C. E., Hassell, J. E., Yamashita, P. S., Fox, J. H., Reber, S. O., Brenner, L. A., et al. (2016) · Current Environmental Health Reports · doi:10.1007/s40572-016-0100-5 · Cited by 172
The role of depressive subtypes within the neuroinflammation hypothesis of major depressive disorder
Woelfer, M., Kasties, V., Kahlfuss, S., & Walter, M. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.034 · Cited by 171
Fancourt, D., Perkins, R., Ascenso, S., Carvalho, L., Steptoe, A., & Williamon, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151136 · Cited by 147
C-Reactive protein as a biomarker for major depressive disorder?
Orsolini, L., Pompili, S., Tempia Valenta, S., Salvi, V., & Volpe, U. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031616 · Cited by 171
Klawonn, A. M., Fritz, M., Castany, S., Pignatelli, M., Canal, C., Similä, F., Tejeda, H. A., Levinsson, J., Jaarola, M., Jakobsson, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2020.12.016 · Cited by 163
Ren, Q., Ma, M., Ishima, T., Morisseau, C. H. P., Yang, J., Wagner, K. M., Zhang, J.-C., Yang, C., Yao, W., Dong, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601532113 · Cited by 165
Zhang, J., Xie, X., Tang, M., Zhang, J., Zhang, B., Zhao, Q., Han, Y., Yan, W., Peng, C., & You, Z. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.07.012 · Cited by 150
Çakici, N., Sutterland, A. L., Penninx, B. W. J. H., Dalm, V. A. S. H., de Haan, L., & van Beveren, N. J. M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.039 · Cited by 162
Altered neuro-inflammatory gene expression in hippocampus in major depressive disorder
Mahajan, G., Vallender, E. J., Garrett, M. R., Challagundla, L., Overholser, J. C., Jurjus, G., Dieter, L., Syed, M., Romero, D. G., Benghuzzi, H., et al. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.11.017 · Cited by 162
Wang, J., Zhang, Y., Chen, Y., Wang, Y., Li, S., Wang, Y., ZHANG, Z.-X., Zhang, J., & Rong, P. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02341-6 · Cited by 164
Kim, Y., & Won, E. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.04.020 · Cited by 160
Therapeutic Strategies for Treatment of Inflammation-related Depression
Adžić, M., Brkic, Z., Mitić, M., Francija, E., Jovicic, M. J., Radulović, J., & Marić, N. P. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170828163048 · Cited by 162
Therapeutic Implications of Brain–Immune Interactions: Treatment in Translation
Miller, A. H., Haroon, E., & Felger, J. C. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.167 · Cited by 152
Microglial dysfunction connects depression and Alzheimer’s disease
Santos, L. E., Beckman, D., & Ferreira, S. T. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.11.011 · Cited by 154
Haroon, E., & Miller, A. H. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_40 · Cited by 153
Metadata
- Authors
- Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J.
- Affiliations
- Research Department P, Aarhus University Hospital, Risskov, Denmark2Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus University Hospital, Risskov, Denmark
- University of Copenhagen (DK)
- St. George's University (GD)
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2014-12-01
- Volume
- 71
- Issue
- 12
- Pages
- 1381
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2156150528
- Semantic Scholar
- 04c60d39fcaf20a7ee393c91def9fcd0fd3f10fc
- Cited by
- 941
- References
- 56
- Citations by year
- 2026: 48 · 2025: 62 · 2024: 74 · 2023: 81 · 2022: 88 · 2021: 106 · 2020: 94 · 2019: 85 · 2018: 104 · 2017: 85 · 2016: 70 · 2015: 43 · 2014: 1
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- green
- pure.au.dk
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- Lundbeckfonden (R155-2014-1724)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- anti-inflammatory therapy, depression, depressive symptoms, nonsteroidal anti-inflammatory drugs, cytokine inhibitors, celecoxib, COX-2 inhibitors, antidepressant effects, adverse effects, remission, treatment response, adults with depression
- MeSH terms
- Anti-Inflammatory Agents, Depression, Humans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
